Palantir Shares Face Scrutiny Amid UK Government Contract Debate

Palantir faces UK political scrutiny over its NHS data platform while securing major US defense contracts and posting 70% revenue growth, highlighting a transatlantic divide.

While Palantir Technologies continues to post impressive financial growth and secure major U.S. defense contracts, its operations in the United Kingdom are drawing significant political scrutiny. Members of the British Parliament have issued a stern warning to the data analytics firm, casting a shadow over its high-value partnership with the National Health Service (NHS).

UK Health Data Contract Sparks Transparency Concerns

Central to the controversy is Palantir’s work on the NHS Federated Data Platform. The arrangement, valued at £330 million, faces persistent criticism from lawmakers and privacy advocates. The core objections focus on a perceived lack of transparency and ethical concerns over whether a company with deep ties to the defense sector should manage highly sensitive national health data.

NHS England has reported operational benefits from the platform. By the end of February 2026, 123 health trusts were utilizing the system, which is credited with facilitating 110,000 additional patient procedures and reducing discharge delays by 12%. However, these claims are undermined by the fact that the underlying data is not publicly accessible, doing little to alleviate the skepticism of critics.

Strong U.S. Performance and Robust Finances

Across the Atlantic, Palantir’s business momentum appears unstoppable. A significant milestone was reached on March 9, 2026, when the Pentagon officially classified the company's Maven AI system as a "Program of Record." This designation guarantees long-term budgetary support and paves the way for broader deployment across all branches of the U.S. military. Management of the contract is scheduled to transition to the U.S. Army by September 30, 2026.

The company’s financial results underscore its powerful market position. For the fourth quarter of 2025, Palantir reported revenue of $1.41 billion, representing a remarkable 70% year-over-year increase. Its U.S. government business alone grew 66% to $570 million. The firm concluded fiscal year 2025 with a formidable $7.2 billion in cash reserves and no debt. Its "Rule of 40" score—a key software industry metric combining growth and profitability—soared to approximately 127%.

Ambitious Targets and Mixed Market Sentiment

Palantir’s leadership has set a highly ambitious long-term goal: to increase annual revenue to between $40 and $45 billion by the early 2030s, a tenfold expansion. The company is betting its Artificial Intelligence Platform (AIP) will be the primary engine for this growth. For the current year, Palantir is targeting commercial revenue in the United States to exceed $3.14 billion.

Market analysts, however, remain divided on the stock’s prospects. While institutional price targets range from $200 to $230 per share, the equity currently trades around $148. This price is roughly 29% below its autumn 2025 highs. Adding to investor caution are insider stock sales totaling approximately $137.75 million over the preceding 90-day period. Consequently, valuation concerns persist as the dominant topic among investors, even as the company’s operational performance accelerates.